Boston Scientific Corp (NYSE:BSX) shares traded -0.07% down during most recent session to reach at the closing price of $40.23. The stock exchanged hands 6.06 Million shares versus average trading capacity of 7.11 Million shares, yielding a market cap of $55.87 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $44.07 within the next 52-weeks. The mean target projections are based on 23 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Boston Scientific Corp (NYSE:BSX) high price target of $48 and with a conservative view have low price target of $39.5.
Credit Suisse “Initiates Coverage On” Boston Scientific Corp (NYSE:BSX) in a research note issued to investors on 12/18/18 to Outperform with price target of $42.
Additionally on 11/28/18 UBS “Initiates Coverage On” Boston Scientific Corp (NYSE:BSX) to Buy setting price target at $45 and on 10/26/18 Argus “Maintained” the stock to Buy at $43. Furthermore on 10/25/18 Canaccord Genuity “Maintained” the stock to Buy at $42.
On the other hand the company has Relative Strength Index (RSI 14) of 61.78 along with Average True Range (ATR 14) of 0.67, Consequently Boston Scientific Corp (NYSE:BSX)’s weekly and monthly volatility is 1.40%, 1.61% respectively. The company’s beta value is at 0.9.
In terms of Buy, Sell or Hold recommendations, Boston Scientific Corp (NYSE:BSX) has analysts’ mean recommendation of 1.5. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Boston Scientific Corp (NYSE:BSX)’s minimum EPS for the current quarter is at $0.33 and can go high up to $0.37. The consensus mean EPS for the current quarter is at $0.36 derived from a total of 21 estimates from the analysts who have weighed in on projected earnings. However the company reported $0.33 earnings per share for the same quarter during last year.
Previously Boston Scientific Corp (NYSE:BSX) reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.02. The company posted an earnings surprise of 5.4%.
Boston Scientific Corp (NYSE:BSX)’s revenue estimates for the current quarter are $2.54 Billion according to 19 number of analysts, for the current quarter the company has high revenue estimates of $2.55 Billion in contradiction of low revenue estimates of $2.53 Billion. For the current year the company’s revenue estimates are $10.7 Billion compared to low analyst estimates of $10.59 Billion and high estimates of $11.09 Billion according to 22 number of analysts.
Currently Boston Scientific Corp (NYSE:BSX)’s shares owned by insiders are 0.3%, whereas shares owned by institutional owners are 93.6%. However the six-month change in the insider ownership was recorded -14.58%, as well as three-month change in the institutional ownership was recorded 0.17%.
Boston Scientific Corp (NYSE:BSX)’s trailing twelve month revenues are $9.82 Billion, whereas its price to sales ratio for the same period is 5.69. Its book value per share for the most recent quarter is $6.3 while its price to book ratio for the same period is 6.39, as for as the company’s cash per share for the most recent quarter is $0.11, however its price to cash per share ratio for the same period is 382.67. The stock has 5 year expected PEG ratio of 2.86 whereas its trailing twelve month P/E ratio is 35.14.